# STARLiT: HCP commentary report

> 64 verified statements (17 from clinicians verified by NPI or staff page) from 3 commentary sources · 8 findings · updated Oct 30, 2026

## Report

- Trial: STARLiT: STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer: A Phase I/II Trial
- NCT ID: NCT06574880
- Registry: https://clinicaltrials.gov/study/NCT06574880
- Sponsor: Angela Y. Jia, MD PhD
- Phase: Phase 1/Phase 2
- Status: Recruiting
- Drugs tested: Lu-PSMA-617 plus SBRT
- Indication: locally advanced prostate cancer
- Version: v1.0.0, edition 1
- Accepted: 2026-10-30
- Last checked: 2026-10-30
- Release hash: 1f41364d04d2f551c4fe35de7d331389098b1f1cd8840f76138a00750d107cf5

## Counts

- HCP commentary sources screened: 12
- Sources cited by verified statements: 4
- Verified statements: 64
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 17
- Findings: 8
- Named people in screened sources (unnamed speakers and accounts not counted): 7
- Voices cited: 7
- Cited voices identity-verified: 7

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

STARLiT asks whether Lu-PSMA-617 combined with stereotactic body radiotherapy can replace androgen-deprivation therapy for locally advanced prostate cancer. Commentary comes from X posts and a podcast with radiation oncologists, including one described on the episode as a principal investigator of STARLiT. The discussion turns on whether ADT replacement can move beyond research, and how research availability, attendance constraints and patient preferences shape SBRT use in high-risk prostate cancer.

## Open Medical Affairs question

What evidence of cancer control, sustained ADT avoidance and patient-reported benefit would justify substitution rather than the escalation described here?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. ADT replacement attracts interest as a research strategy, not an established treatment option
- F2. An unnamed combination-safety endorsement must not become a STARLiT safety conclusion
- F3. PSMA-positive nodes motivate systemic and regional escalation in one practice, with explicit evidentiary limits
- F4. PSMA staging changes treatment decisions, but negative scans and stage migration limit interpretation
- F5. PET–MRI complementarity supports dose personalization, but better delineation is not proven clinical benefit
- F6. High-risk SBRT use is qualified by research availability, attendance constraints and patient preference
- F7. Localization, margins and spacer decisions remain equipment- and operator-dependent
- F8. Quality-of-life and economic value remain questions about treatment consequences, not scan price alone

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 8 | 8 | 3 | 4 | recorded | 3 |
| F2 | 2 | 2 | 1 | 2 | none recorded | 3 |
| F3 | 6 | 6 | 1 | 2 | recorded | 3 |
| F4 | 10 | 7 | 1 | 3 | none recorded | 3 |
| F5 | 11 | 8 | 1 | 4 | none recorded | 3 |
| F6 | 10 | 8 | 1 | 3 | recorded | 4 |
| F7 | 7 | 7 | 1 | 3 | none recorded | 3 |
| F8 | 9 | 3 | 1 | 3 | none recorded | 3 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 3 | 0 | 1 | 0 | 4 | 8 | 2 | 1 post or article, 1 podcast or video, 1 registry | yes |
| F2 | 2 | 0 | 0 | 0 | 0 | 2 | 1 | 1 post or article | yes |
| F3 | 1 | 2 | 3 | 0 | 0 | 6 | 1 | 1 podcast or video | yes |
| F4 | 4 | 2 | 3 | 1 | 0 | 10 | 0 | 1 podcast or video | yes |
| F5 | 4 | 1 | 2 | 1 | 3 | 11 | 1 | 1 podcast or video | yes |
| F6 | 3 | 0 | 3 | 0 | 4 | 11 | 1 | 1 podcast or video | yes |
| F7 | 2 | 2 | 3 | 0 | 0 | 7 | 0 | 1 podcast or video | yes |
| F8 | 1 | 2 | 0 | 1 | 5 | 11 | 2 | 1 podcast or video | yes |

### Trial dimensions

- Primary endpoint: Phase I: Maximum tolerated dose (MTD) of Lu-PSMA-617: F1 (1 shared claims)
- Primary endpoint: Phase II: Androgen deprivation therapy (ADT)-free survival: F1 (1 shared claims)
- Secondary endpoints: F1 (1 shared claims), F8 (1 shared claims)
- Population and setting: F1 (3 shared claims), F6 (2 shared claims)
- The comparison: F1 (3 shared claims)
- Safety and tolerability: F1 (1 shared claims)
- Design and conduct: F1 (2 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

### F1. ADT replacement attracts interest as a research strategy, not an established treatment option

A radiation oncologist, described on the podcast as a STARLiT principal investigator, sets out the question of replacing ADT with radioligand therapy alongside definitive radiotherapy.

Source: podcast, 2025-01-15.

### F6. High-risk SBRT use is qualified by research availability, attendance constraints and patient preference

A radiation oncologist on the podcast asks about use of an alternative prostate radiotherapy schedule.

Source: podcast, 2025-01-15.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 8 | Titles free |
| Detailed analysis | 9 sections | Paid |
| Verified statements with short source quotes and links | 64 | Paid |
| Trial aspects mapped | 14 | Free |
| Sources with links | 4 | Counts free |
| Speaker attribution for cited voices | 7 | Paid |

## Trial aspects

14 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Phase I: Maximum tolerated dose (MTD) of Lu-PSMA-617 | discussed | 1 | 1 |
| Primary endpoint: Phase II: Androgen deprivation therapy (ADT)-free survival | discussed | 1 | 1 |
| Secondary endpoints | discussed | 2 | 2 |
| Population and setting | discussed | 4 | 2 |
| The comparison | discussed | 3 | 2 |
| Safety and tolerability | discussed | 1 | 1 |
| Design and conduct | discussed | 2 | 2 |
| PSMA staging, occult disease and atypical uptake | discussed | 10 | 1 |
| Nodal treatment and endocrine-intensification alternatives | discussed | 6 | 1 |
| PET–MRI target definition and local dose personalization | discussed | 11 | 1 |
| Access, fractionation and research versus routine care | discussed | 10 | 1 |
| Margins, localization, monitoring and spacers | discussed | 7 | 1 |
| Country-specific imaging economics and diagnostic radiation exposure | discussed | 9 | 1 |
| Unnamed SBRT–Lu-177-PSMA-617 safety endorsement and advanced-disease ADT-impact hopes | discussed | 2 | 1 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 9 | 2 |
| Bluesky threads | 2 | 0 |
| Podcasts | 1 | 1 |
| Registry (primary source, cited for context) | not screened | 1 |

- Screened window: 2025-01-15 to 2026-09-30
- Cited window: 2025-01-15 to 2025-09-30
- Retrieved: 2026-10-30

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: STARLiT: STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer: A Phase I/II Trial
- Registry: NCT06574880 (https://clinicaltrials.gov/study/NCT06574880)
- Study IDs: CASE7824
- Sponsor: Angela Y. Jia, MD PhD
- Design: Phase 1/Phase 2 · interventional, na, single group, phase1, phase2
- Status: Recruiting
- Enrollment: 45 (estimated)
- Start: 2025-05-13 (actual)
- Primary completion: 2026-09-01 (estimated)
- Primary endpoint: Phase I: Maximum tolerated dose (MTD) of Lu-PSMA-617 (4 weeks after final dose of treatment (treatment expected to last up to six months))
- Primary endpoint: Phase II: Androgen deprivation therapy (ADT)-free survival (3 years post treatment)
- Intervention: Lu-PSMA-617 (drug)
- Intervention: 5-fraction Stereotactic Body Radiation Therapy (SBRT) (radiation)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Some clinician views in the sources used in this report are not yet captured as evidence in this edition.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 43 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits apply, so some matching discussion may be missing.
- The sources reviewed for this edition do not represent all HCPs or all public discussion; additional relevant views may be absent.
- Some short passages were not fully assessed, and one additional potentially relevant source was not read. References that do not name the trial or use different wording may also be missing.
- No full study protocol or exact-trial results publication was identified. Registry methods and presentation objectives cannot establish observed treatment benefit or safety.
- The available material does not establish regulatory authorization for this use.
- The trial-unnamed February X exchange does not establish which study supplied its safety data or whether its advanced-disease discussion matches STARLiT's population.
- Local practice, access restrictions and adoption forecasts reflect their source timing and settings; they should not be read as current or universal policies.
- A speaker's principal-investigator involvement and the presenter's involvement are descriptions made by the sources, not independently established trial roles.
- Not yet captured in this edition: a question about future integration and universal adoption of SBRT and PSMA PET.
- Not yet captured in this edition: a view on biological testing to identify patients most likely to benefit from treatment.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-30: current edition, corrected 2026-10-30
  - Correction 2026-10-30: Corrected to match the delivered report: the limitations; the sample findings; the report description. The trial's name is spelled as its investigators write it, “STARLiT” (NCT06574880), outside quotations (was “STARLIT”).

Last checked for new commentary 2026-10-30. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (64 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (7 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/starlit-nct06574880
- Agents: POST https://www.erudio.com/api/orders with {"report": "starlit-nct06574880", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=starlit-06574880

## Cite

Erudio Health. STARLiT (NCT06574880): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 30, 2026. https://www.erudio.com/reports/starlit-nct06574880

## Machine access

- JSON: https://www.erudio.com/reports/starlit-nct06574880.json
- Markdown: https://www.erudio.com/reports/starlit-nct06574880.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "starlit-06574880"}`